FAQs

Helping Prevent Diabetic Foot-Ulcers and Lower-Limb Amputations,

Using Non-Invasive AI Medical Devices, and Organic Treatments²"

FDA-Cleared Medical Devices:

Amount Raised: $86,947 | Raise Goal: $500,400

FDA-Cleared Medical Devices:

Company Overview:

🚀 Experienced Founder: With a track record of 30+ years in health and wellness and 40 years in growing and scaling companies, our founder brings deep expertise to our mission.

🌐 US Government Registration: In August 2023, we were registered as a supplier to U.S. Government Agencies like the VA, DOD, HHS, and Indian Health Services, with the issuance of our DOD Commercial and Government Entity (CAGE) Code 9N4Y6, opening doors to substantial marketing opportunities to all governmental agencies.

💼 FDA Cleared Medical Devices: In March 2023, we added a portfolio of FDA cleared Class I & Class II Medical Devices, enabling non-invasive early detection of chronic inflammatory diseases, including cardiovascular issues, neuropathy, diabetic foot ulcers and other ailments.

🔬 Patented Medical Food: In January 2022, added a patented medical food (plant-based oils) for managing major health conditions, available exclusively through licensed MDs.

💰 Revenue Growth: Over the past 5 years, we've generated almost $1 million in sales—all organically, from just our Over-The-Counter patented supplement without any advertising spent as a sole-proprietor. (Past performance is not indicative of future results)

📊 Proven by Research: Our solutions are backed by clinical and evidence-based studies, providing real proof of concept in human trials.

🤝 Established Customer Base: We have a thriving customer base, including wholesalers, retailers, and healthcare practitioners.

Reasons to Invest:

🚀 Experienced Founder: With a track record of 30+ years in health and wellness and 40 years in growing and scaling companies, our founder brings deep expertise to our mission.

🌐 US Government Registered: In August 2023, we were registered as a supplier for U.S. Government Agencies like the VA, DOD, HHS, and Indian Health Services, with the issuance of our DOD Commercial and Government Entity (CAGE) Code 9N4Y6, opening doors to substantial marketing opportunities to all governmental agencies.

💼 FDA Cleared Medical Devices: In March 2023, we added a portfolio of FDA cleared Class I & Class II Medical Devices, enabling non-invasive early detection of chronic inflammatory diseases, including cardiovascular issues, neuropathy, diabetic foot ulcers and other ailments.

🔬 Patented Medical Food: In January 2022, added a patented medical food (plant-based oils) for managing major health conditions, available exclusively through licensed MDs.

💰 Revenue Growth: Over the past 5 years, we've generated almost $1 million in sales—all organically, from just our Over-The-Counter patented supplement without any advertising spent as a sole-proprietor. (Past performance is not indicative of future results)

📊 Proven by Research: Our solutions are backed by clinical and evidence-based studies, providing real proof of concept in human trials.

🤝 Established Customer Base: We have a thriving customer base, including wholesalers, retailers, and healthcare practitioners.

Amount Raised: $86,947 | Raise Goal: $500,400

Our Veterans Have Been Facing a Silent Crisis¹:

1. Rates of Limb-Loss and Amputations: 

More than 796,000 veterans have lost their lives due to Diabetic Foot Ulcers "DFU" and Lower-Limb Amputations "LLA".¹

3. Post-Surgical Mortality Rate: 

 Veterans Health Administration indicates there is a 64-71% mortality rate within 3-years after a Lower Limb Amputation.¹

2. The Significance of This Crisis:

More Veterans have lost their lives from lower-limb amputations, than every solider killed in combat since World War 1.¹

4. Methods of Detection are Limited:

Diabetic Foot-Ulcers are difficult to detect in their early stages and are usually only treated once the wound is already manifested.¹

Now, we can detect the early-stages of a diabetic foot-ulcers² and other conditions with the

FDA Cleared - Thermal Imaging System with AI Capabilities: 

FDA Class 1 - Medical Thermography System

The ThermaLens™ - IRIS-XP™ combines a high-resolution, infrared camera, with a proprietary artificial intelligence software for fast, accurate, and automatic disease detection.³ 

This system can precisely measures a patient's heat signature to within a fraction of a degree, then use machine learning to cross-reference this data with our extensive database of verified medical cases.⁴

This enables for the early detection of conditions such as:

Diabetic foot ulcers, circulatory diseases, neuropathy, chronic inflammation, peripheral artery disease, and more.

Reduce Amputations:

ThermaLens™ - IRIS-XP™ detects early signs of conditions like diabetic foot ulcers, reducing the need for amputations.

Fewer Hospital Visits:

With early and accurate detection, veterans face fewer complications, reducing hospital admissions.

Cost-Efficiency:

Early interventions curtail prolonged treatments, offering substantial savings for the VA and an efficient use of resources.

Lower Rates of Death:

By pinpointing conditions leading to amputations, we can play a pivotal role in decreasing mortality rates among veterans.

ThermaLens™ - IRIS-XP™ can visualize chronic pain, a condition often difficult to diagnose. 
Additionally, it offers the capability to present comparative before-and-after images.

General System Benefits:
Seamless Integration: With PACS/EMR compatibility, ThermaLens™ - IRIS-XP™ can be effortlessly integrated into existing healthcare systems, ensuring a smooth workflow. 

Device Versatility: ThermaLens™ - IRIS-XP™ comes in various packages for a range of settings and environments – from large hospitals to mobile units.

​Expand Healthcare Offerings: Medical facilities can diversify their services, catering to a broader range of conditions.

​State-of-the-Art Technology: With the growing interest in thermography, ThermaLens™ - IRIS-XP™ is one of the first standardized medical thermography machines for large-scale production and professional use.
CUSTOM JAVASCRIPT / HTML

ThermaLens™ - IRIS-XP™ - System Packages:

(Laptops for the Clinic and Mobile Unit are included)

ThermaLens™ - Hospital 

Remote work station + vertically motorized stand with 360° rotating camera mount 

ThermaLens™ - Clinic

Vertically motorized stand + tri-pod + travel case and windows laptop with ThermaLens™ software

ThermaLens™ - Mobile Field Unit

Includes tri-pod + travel case and windows laptop with ThermaLens™ software

Comprehensive care for our veterans doesn't stop there, 
because addressing the underlying conditions is equally as important!

Introducing Brivanta™ - The Organic Medical Food

Brivanta™ formerly known as "EZTREK®" is a plant-based, cold-pressed, and organic Essential Fatty Acid formulation, specifically designed as a medical food for those with an impaired "Delta-6 Desaturase Enzymatic Pathway".

Targeted Relief: Provides relief to those battling chronic inflammatory diseases due to a Delta-6 Desaturase Pathway impairment.

Physician Supervised: This medical food is exclusively available under the guidance of a licensed physician.

Patented & Proven: Patents granted in the United States and Canada, backed by over 20 years of evidence-based research and development.

​Easy Administration: Brivanta®, is an oil that remains liquid even at cold temperatures, and should be stored in the fridge to prevent rancidity. It comes with a small measuring spoon for easy and precise dosing.

As we age, this Delta-6 Desaturase enzymatic pathway is known to become impaired.⁷ This impairment has been linked to multiple chronic inflammatory diseases and immune-deficiencies.

With over two decades in development, Brivanta™ offers a targeted dietary management approach for chronic inflammation. Today, the modern diet unknowingly may cause chronic inflammation leading to ill-health.⁶⁷  Inflammatory response starts with the Delta-6 Desaturase enzymatic pathway.⁹

VHA Epidemic Report on DFU's and Case-Studies Using Brivanta™ or it's Precursor Product PEOs.

Brivanta™ has been rebranded and was called EZTREK® before.

Veteran Diabetic Foot Ulcer (DFU) Epidemic: 
A U.S. Department of Veterans Health Administration (VHA) Hyperbaric Oxygen Therapy (HBOT) Services Review

The increase in the Worldwide Diabetic Patient population at risk for Lower Limb Amputation
(LLA) is growing exponentially. The Diabetic Foot Ulcer (DFU) epidemic increase in US Veteran Diabetes population due to poor clinical management is substantially greater than the civilian Medicare population resulting in an alarming LLA rate which is largely unnecessary. 

EZTREK® Novel Diabetic Foot-Ulcer Treatment - White Paper

It is well documented that diabetic patients have impaired delta-6 desaturase (D6D) metabolic pathways from impaired insulin production. In particular, this metabolic defect causes a poor anti-inflammatory response in Type I patients. Even with insulin therapy, the pathway is still deficient. Type II patients also have significant impairment of D6D activity. Diabetic foot ulcer (DFU) wound healing is impaired

Dr. Oscar Barreto DPM, NP, FACFAS
Private Clinical Study - EZTREK®

Five Clinical Case Studies involving Diabetic Foot Ulcers

2016 Chronic Wound Healing -
A Case Series study with an ingestible, calibrated formulation of PLANT-BASED LIPIDs (the adjuvant) at a University Wound Healing & Hyperbaric Center has been completed. (PEOs)

With all 14 patients taken as a group for statistical analysis, both wound surface area and wound volume statistically improved (decreased) with the PEO adjuvant. The magnitude of the effect was significant, and the percentage of the population it worked in was also significant.

Chronic Wound / Diabetic Ulcer Healing / Surgical Healing: A New Plant-Based Treatment Clinically Effective in Just 30 Days
TOWNSEND LETTER - APRIL 2016

Just 30 Days to Clinical Effectiveness in Healing Diabetic Ulcers and Underlying Pathophysiologic Disorders, Increasing Blood Flow, and Improving Surgical Outcomes with Case Studies

Pressure Ulcer Whitepaper:

EZTREK® – LIPID BASED ORAL MEDICATION FOR DERMAL WOUND HEALING 

$50B per year is spent on wound care. Chronic diabetic foot ulcers (DFUs) alone represent a substantial financial burden to the health care system costing up to $13B per year.  Both hospital costs and lengths of stay are significantly higher for military patients who develop pressure ulcers during hospitalization – more than $50,000 per patient and $1.5B annually. (2006)  

Additional Medical Conditions We Plan To Target:

Oxygen4Life™, Inc. has use-cases for some of the most detrimental conditions that affect not just veterans, but the general population as well. 

From diabetic foot ulcers to chronic inflammation, our solutions address a wide range of health concerns that affect hundreds of millions around the world.

Use the links below to view the sources of these statistics: 

Minimum Investment - $108

The Team Behind Oxygen4Life™, Inc.

The Oxygen4Life™, Inc. team is experienced in medical sales, marketing, web development, manufacturing, graphic design, order fulfillment, and more. We specialize in providing non-drug remedies that treat the root-cause of problem, not just the symptoms.

Mike Maunu -
CEO/President & Founder

*Click here to learn more about Mike*

Alex Maunu -
Co-Founder, Director of video/content

*Click here to learn more about Alex*

Nate Thorne, E.A.  -
Chief Financial Officer (CFO)

*Click here to learn more about Nate*

Dionisio Gomez -
Director of online marketing

*Click here to learn more about Dionisio*

Ryan Cinches -
Director of Internet Technology

*Click here to learn more about Ryan*

Phil Chavanne -
Consultant in Web Design & Analytics

*Click here to learn more about Phil*

Cindi Webb -
Director of Training & Onboarding for medical practitioner's

*Click here to learn more about Cindi*

Board of Advisors:

David Blackledge

Government Contracting and Growth Advisor

David Blackledge is fulltime faculty Professor at Grand Canyon University’s College of Business and Of Counsel at Davis Miles McGuire Gardner, a full service law firm operating in the southwest US.  Dave focuses his practice on startup and emerging businesses particularly in various technology markets. This includes counseling business owners from entity formation through raising capital and company growth, and on business associations with other partnerships, distributors, licensees, and general business relationships.  
USE OF FUNDS:
Research & Development: Funding white paper studies for early detection of neuropathy and Diabetic Foot Ulcers (DFUs) using ThermaLens™.  Exploring treatment options with PEOs or EZtrek medical food. 

Inventory: Purchasing medical devices including ThermaLens™, Smart Pulse, and Max Pulse devices for comprehensive health monitoring and treatment.

Medical Conferences & Events: Attending key medical and tech conferences, including booth setup, marketing materials, travel, and accommodation.

Lunch and Learns: Hosting educational sessions for medical professionals, covering venue, logistics, and educational materials.

Marketing & Advertising: Focused digital advertising, SEO, content marketing, and PR campaigns to improve online visibility and customer acquisition.
Investor Relations & Capital Raising: Specialized marketing initiatives aimed at attracting investors through equity crowdfunding and 506C capital raise.

Sales & Customer Support: Training the sales team and developing a robust customer support infrastructure.

Regulatory Compliance: Legal fees for patents, FDA clearances, and other regulatory requirements. Acquiring additional certifications.

Working Capital & Miscellaneous: Inventory buildup for faster delivery and covering operational expenses.
Company Overview:

Since our incorporation in February 2022 and launch in February of 2023, we have been committed to reshaping the health and wellness industry through our groundbreaking products, which now include state-of-the-art medical devices and patented organic plant based supplements and a patented medical food .

Our portfolio now features a range of advanced AI-driven health technologies, including the Smart Pulse wellness device, the FDA Cleared Class II Medical Device (Max Pulse), and the ThermaLens™ Medical Thermography Imaging System. 

These cutting-edge devices have expanded our capabilities and positioned us as pioneers in non-invasive health monitoring.

Moreover, we have strategically embarked on a government sales strategy with the attainment of our DOD Commercial and Government Code that is enabling us to tap into government agencies such as the VA, DOD, HHS, the Indian Health Services and others.

 This expansion holds immense potential for growth and market penetration.

With a robust infrastructure in place, encompassing distribution agreements, GMP-certified manufacturing, warehousing, and efficient order fulfillment, we are poised for success. 

Now, we are inviting investors to join us on this remarkable journey as we elevate our brand to new heights.

By investing in Oxygen4Life™, Inc. you will empower us to amplify our advertising efforts, extend the reach of our direct-to-consumer and wholesale marketing campaigns, and onboard skilled professionals to support and scale our operations. 

Our focus remains steadfast on expanding our marketing initiatives, driving sales, and establishing strategic collaborations with medical practitioners and other key players in the industry.

In tandem with enhancing our e-commerce brand, we are gearing up to implement robust systems for consistent product promotion to our target markets, widening our audience reach. 

This growth trajectory will be supported by the addition of new team members and interns, ensuring that we have the requisite resources to meet burgeoning consumer demand and thrive in a competitive market.

This is your chance to be part of a transformative journey that promises to reshape health and wellness. Don't miss out on this exciting opportunity to make a meaningful impact and be part of something truly exceptional. 

Your investment in Oxygen4Life™, Inc. is an investment in the future of healthcare.

(Forward looking Projections cannot be guaranteed. See broader Forward Looking Statement Disclosure at the endnote)
Click Here to View the disclosure

It’s pioneers like YOU who can help us pave the way for different results in healthcare. 

This is the ground-floor opportunity for you to join Oxygen4Life™, Inc. as we move into our next phase of aggressive company growth. 

Investment Packages and Bonuses:

All investments over $500 receive: 1 bottle PEO capsules & 1 bottle of PEO liquids, 1 bottle of herbal capsules, 1 bottle of mineral capsules. Informational pdfs and the PEO Solution book or 24-Hour Diet book in digital form! $154.45 Total Value

Disclaimers:

* In order to receive perks from an investment, one must submit in a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur after the offering is completed.

** Investors will only receive a single bonus, which will be the highest bonus category for which they are eligible.

*** EZTREK™ is only available through a licensed medical practitioner and is not included in the product packages.

**** Lifetime discount cannot be combined with any VIP Rewards discount a customer might earn when shopping online. Choose highest discount at time of order.

***** Discounts are for retail customers only.

Investment Details:

Amount:

Bonuses:

Perks:

Retail Value:

$500+

Supplement & Book Package

(5% lifetime discount on consumer products)

$154.45 Total Value

$1,000+

Supplement & Book Package

(10% lifetime discount on consumer products)

$154.45 Total Value

$2,500+

Supplement & Book Package

(5% bonus shares + 15% lifetime discount on consumer products)

$154.45 Total Value

$5,000+

This package includes (1) Zoom call with Founders. 

(10% bonus shares + 20% lifetime discount on consumer products)

Supplement & Book Package with 2x the amount of product. $381.35 Retail Value

$10,000+

A day and dinner with the Founder Team in Scottsdale, AZ and a one-night stay at a premier Hyatt Hotel.

(10% bonus shares + 20% lifetime discount on consumer products)

Supplement & Book Package with 2x the amount of product. $381.35 Retail Value

*Does not include transportation*

$25,000+

A day and dinner with the Founding Team in Scottsdale, AZ. We will fly you round-trip from anywhere in the Continental USA and will include a two-night stay at a premier Hyatt Hotel. This also will include the choice of a round of golf or a spa day.

(15% bonus shares + 20% lifetime discount on consumer products) 


Supplement & Book Package with 2x the amount of product. $381.35 Retail Value

*Includes transportation for (1)*

$50,000+

A day and dinner for (2) the Founding Team in Scottsdale, AZ. We will fly you round-trip from anywhere in the Continental USA and will include a two-night stay at a premier Hyatt Hotel. This also will include the choice of a round of golf or a spa day.

(20% bonus shares + 25% lifetime discount on consumer products)


Supplement & Book Package with 2x the amount of product. $381.35 Retail Value

*Includes transportation for (2)*

Company Milestones:

Jan. 13, 2023

Day of Launch with DealMaker Securities LLC

Jan. 15, 2023

Minimum requirement of raising $10,000.20 completed

Jan. 19, 2023

Founder & CEO Mike Maunu presents Health Webinar to members of the 'Silicon Valley Health Institute'

Feb. 20, 2023

Company launches their 100,000 Shares of Class B Common Stock with their Give-A-Way Promotion

April 4, 2023

(End of Stock Give-A-Way Promotion)
Shares Given Were Class B Common

1st: Nate Thorne - 50,000 shares
2nd: Troy Vanderhoof  - 30,000 shares
3rd: Andrew Croot - 20,000 shares

May 5, 2023

Nate Thorne has been added to the  Oxygen4Life™, Inc. team as the new Chief Financial Officer (CFO)

June 29, 2023

Oxygen4Life™, Inc. presented and exhibited it's products at the Global Capital Network event in Newport Beach, CA.

August 1, 2023

Approved by SAM.gov, the first step to providing our products and services to government agencies and Veterans Assistance.

August 14th, 2023  

Oxygen4Life™, Inc. obtains its CAGE Code and NOW has the ability to sell its products to U.S. government agencies and military branches for the next 5-years.

September 27th, 2023

We unveiled our brand-new office to 50+ potential investors, as we embarked on the next chapter of our mission to combat global health crises.

October 4, 2023

CEO of Oxygen4Life™, Inc. was re-invited  to presented it's products at the most recent Global Capital Network event in Newport Beach, CA.

October 11, 2023

***Rolling close***

November 9, 2023

CEO Mike Maunu presented at the 2023 International Healthcare Summit for Aid-to-Ukraine via Zoom. 

Click here to read the press-release

November 17, 2023

Whiskey and chocolate investor event with updates regarding the DoD and U.S. Army Medical Research Acquisition Group. Thank you to our equity crowdfunding attorney and Chocolate Savant, Mark Svejda for providing the whiskey/chocolate pairings.

November 24, 2023

We successfully closed our third round of funding at at a $5,000,000 pre-money valuation. New round is at a $15,000,000 post money valuation and is represented in the new share price of $1.80.

November 29, 2023

Oxygen4Life, Inc. sponsors networking event in Tempe, AZ, presenting Oxygen4Life, Inc. to the 100+ event attendees.

December 6-9, 2023

Exhibitor and presenter at the Desertfoot podiatry conference with 600+ attendees, hosted at The Sheraton in Downtown Phoenix.

Frequently Asked Questions:

CUSTOM JAVASCRIPT / HTML
CUSTOM JAVASCRIPT / HTML
Copyrights 2023 | All Rights Reserved 
| Oxygen4life.com | Oxygen4Lifeinc.com | Oxygen4Life™, Inc. |
These statements have not been evaluated by the Food and Drug Administration. These products and statements are not intended to diagnose, treat, cure or prevent any disease or illness. These statements should not be taken as medical advice, you should always consult your doctor before making any health changes, decisions and/or drawing any health conclusions. 

This site is not a part of the Facebook website or Facebook Inc. Additionally, This site is NOT endorsed by Facebook in any way. FACEBOOK is a trademark of FACEBOOK, Inc.

Citations and References:

¹ Ertl JP, Brackett WJ, Ertl W, Pritchett JW, et al. "Lower-Extremity Amputations". Indiana University School of Medicine; Chief of Orthopedic Surgery, Wishard Hospital; Chief, Sports Medicine and Arthroscopy, Indiana University School of Medicine. Medscape. 2023 Jul 26. Available from: https://emedicine.medscape.com/article/1232102

² Kaselimi M, Protopapadakis E, Doulamis A, Doulamis N. "A review of non-invasive sensors and artificial intelligence models for diabetic foot monitoring". National Technical University of Athens, School of Rural, Surveying and Geoinformatics Engineering, Athens, Greece. Frontiers in Physiology, Computational Physiology and Medicine. 2022 Oct 21. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635839/

³ Khandakar A, Chowdhury MEH, Reaz MBI, Ali SHMd, Abbas TO, Alam T, Ayari MA, Mahbub ZB, Habib R, Rahman T, Tahir AM, Bakar AAA, Malik RA. "Thermal Change Index-Based Diabetic Foot Thermogram Image Classification Using Machine Learning Techniques". Department of Electrical Engineering, Qatar University, Doha. Sensors. 2022 May 30. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915003/

⁴ Aliahmad B, Tint A, Arjunan SP, Rani P, Kumar D, Miller J, Zajac J, Wang G, Ekinci E. "Is Thermal Imaging a Useful Predictor of the Status". Journal of Diabetes Science and Technology. 2018 Sep 26. Available from: https://www.semanticscholar.org/paper/Is-Thermal-Imaging-a-Useful-Predictor-of-the-Status-Aliahmad-Tint/fd2dd26a4cfa3e17dd0fc14e6ba6ccbf3a9da9b1

⁵ Halbleib K, et al. "Activation of the Unfolded Protein Response by Lipid Bilayer Stress". Molecular Cell. 2017 Aug 17;67(4):673-684.e8. Available from:

⁶ Torres M, Parets S, Fernández-Díaz J, Beteta-Göbel R, et al. "Lipids in Pathophysiology and Development of the Membrane Lipid Therapy: New Bioactive Lipids". Department of Biology, University of the Balearic Islands. Membranes (Basel). 2021 Dec; 11(12): 919. Available from: https://pubmed.ncbi.nlm.nih.gov/34940418/

⁷ Horrobin DF. "Loss of D-6 desaturase activity as a key factor in aging". Medical Hypothesis. 1981 Sep;7(9):1211-20. Available from: https://www.sciencedirect.com/science/article/abs/pii/0306987781900645

⁸ Anton SD, Heekin K, Simkins C, Acosta A, et al. "Differential effects of adulterated versus unadulterated forms of linoleic acid on cardiovascular health". Department of Aging and Geriatric Research, University of Florida. J Integr Med. 2013 Jan; 11(1): 2–10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747367

⁹ Lee JM, Lee H, Kang SB, Park WJ, et al. "Fatty Acid Desaturases, Polyunsaturated Fatty Acid Regulation, and Biotechnological Advances". Department of Horticultural Science, Kyungpook National University. Nutrients. 2016 Jan 4; 8(1): 23. Available from: https://www.mdpi.com/2072-6643/8/1/23 
Oxygen4Life, Inc. is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Title III of the JOBS Act and Regulation CF. A copy of the Form C that forms a part of the Offering Statement may be obtained from: Form C

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Any past performance described is not indicative of future results. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.


DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 105 Maxess Road, Suite 124, Melville, NY 11747, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA's BrokerCheck. DealMaker Securities LLC does not make investment recommendations. DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer. DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor's documentation for this investment. DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing. DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself. Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

This website contains forward-looking statements. These statements may include the words “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate”, “project”, “will”, “may”, “targeting” and similar expressions as well as statements other than statements of historical facts including, without limitation, those regarding the financial position, business strategy, plans, targets and objectives of the management of Oxygen4Life, Inc. (the "Company") for future operations (including development plans and objectives). Such forward-looking statements involve known and unknown risks, uncertainties and other important factors which may affect the Company's ability to implement and achieve the economic and monetary policies, budgetary plans, fiscal guidelines and other development benchmarks set out in such forward-looking statements and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future policies and plans and the environment in which the Company will operate in the future. Furthermore, certain forward-looking statements are based on assumptions or future events which may not prove to be accurate, and no reliance whatsoever should be placed on any forward-looking statements in this presentation. The forward-looking statements in this website speak only as of the date of the Company's initial Form C, and the Company expressly disclaims to the fullest extent permitted by law any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Attributes:

CUSTOM JAVASCRIPT / HTML